search
Back to results

Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst

Primary Purpose

Benign Thyroid Nodule, Thyroid Lump, Thyroid Cyst

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Polidocanol
Alcohol
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Benign Thyroid Nodule

Eligibility Criteria

10 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Single cystic or predominantly cystic nodules. Pressure symptoms or cosmetic problems. No malignant or indeterminate cytologic results after ultrasound-guided fine-needle aspiration. Normal serum thyroid hormone levels Exclusion Criteria: Association of a nodules showing malignant features on us examinations. Malignant or indeterminate cytologic results after ultrasound-guided fine-needle aspiration. Abnormal serum thyroid hormone levels

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Polidocanol group

    Alcohol group

    Arm Description

    Polidocanol is injected in the thyroid cyst under ultrasound guidance.

    Alcohol is injected in the thyroid cyst under ultrasound guidance.

    Outcomes

    Primary Outcome Measures

    Size of the thyroid cystic nodule after sclerosing agent injection (polidocanol versus alcohol)
    Size of the thyroid cyst is measured by ultrasound after 3 months of sclerosing agent injection

    Secondary Outcome Measures

    Full Information

    First Posted
    February 14, 2023
    Last Updated
    March 22, 2023
    Sponsor
    Assiut University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05798936
    Brief Title
    Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst
    Official Title
    Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous Ultrasound Guided Treatment of Benign Thyroid Cyst
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    April 1, 2023 (Anticipated)
    Primary Completion Date
    May 1, 2025 (Anticipated)
    Study Completion Date
    June 1, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Assiut University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This study aims to compare the efficacy and safety of ultrasound-guided percutaneous ethanol injection and percutaneous polidocanol injection for the treatment of benign cystic and predominantly cystic thyroid nodules.
    Detailed Description
    Thyroid nodules are characterized by excessive structural growth, functional transformation, and/or cystic degeneration of one or several areas within the gland. According to various studies, 15-30% of thyroid nodules are cystic or predominantly cystic. Around 5% of patients with thyroid nodules may experience compressive symptoms or cosmetic concerns, and treatment may be required in these cases. Simple aspiration is generally the initial management for the purpose of diagnosis and cyst volume reduction. However, the recurrence rate has been reported to be high (40% to 59%), depending on the number of aspirations and extent of fluid evacuation. After simple fine-needle aspiration, most cystic lesions (around 80%) refill and enlarge over time. Surgery is a long-established therapeutic option for benign thyroid nodules. However, the cost of thyroid surgery, risk of temporary or permanent complications, and impact on quality of life remain relevant concerns. Ultrasound-guided percutaneous ethanol injection (PEI) The mechanism of ethanol sclerotherapy is that ethanol induces cellular dehydration and protein denaturation, which are followed by coagulation necrosis, reactive fibrosis, and small-vessel thrombosis. As regard (PEI)Pain is the most common side effect, other mild side effects or complications occurred in small numbers of patients like: Facial flushing, Mild dizziness, Intracystic haemorrhage, drunken sense, Perithyroidal leakage. There are other side effects, including transient vocal cord palsy, respiratory distress requiring emergency surgical treatment, and venous thrombosis, in sporadic cases. Percutaneous Polidocanol sclerotherapy (PPI) may be a potential alternative to ethanol for the treatment of benign cystic and predominantly cystic thyroid nodules.Polidocanol is a liquid detergent sclerosant developed in 1936 as a topical and local anaesthetic consisting of 95% hydroxy poly ethoxydodecane and 5% ethyl alcohol. It has been used as a treatment for hemorrhoidal disease, venous malformations, symptomatic hepatic cysts, renal cysts, gastric varices, and digital mucous cysts. The mechanism of treating cyst is probably destroying endothelial cells of capsular wall which causes aseptic inflammation; thus endothelial tissue atrophies and cyst cavity adhere and occlude. The side effects are mild including mild localized pain and mild or moderate fever after PPI. So, PPI could be a safe and effective alternative to treat benign cystic or predominant cystic thyroid nodules.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Benign Thyroid Nodule, Thyroid Lump, Thyroid Cyst

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Model Description
    Based on determining the main outcome variable, the estimated minimum required sample size is 30 patients (15 patient in each group). The sample was calculated using G*power software 3.1.9.2., based on the following assumptions: Main outcome variable is the difference between mean value of: Group (A): 15 patients will be treated by Ultrasound-Guided Percutaneous Polidocanol Injection Group (B): 15 patients will be treated by Ultrasound-Guided percutaneous ethanol injection
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Polidocanol group
    Arm Type
    Experimental
    Arm Description
    Polidocanol is injected in the thyroid cyst under ultrasound guidance.
    Arm Title
    Alcohol group
    Arm Type
    Experimental
    Arm Description
    Alcohol is injected in the thyroid cyst under ultrasound guidance.
    Intervention Type
    Drug
    Intervention Name(s)
    Polidocanol
    Other Intervention Name(s)
    Polidocanol solution
    Intervention Description
    Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
    Intervention Type
    Drug
    Intervention Name(s)
    Alcohol
    Other Intervention Name(s)
    Alcohol Ethyl
    Intervention Description
    Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
    Primary Outcome Measure Information:
    Title
    Size of the thyroid cystic nodule after sclerosing agent injection (polidocanol versus alcohol)
    Description
    Size of the thyroid cyst is measured by ultrasound after 3 months of sclerosing agent injection
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    10 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Single cystic or predominantly cystic nodules. Pressure symptoms or cosmetic problems. No malignant or indeterminate cytologic results after ultrasound-guided fine-needle aspiration. Normal serum thyroid hormone levels Exclusion Criteria: Association of a nodules showing malignant features on us examinations. Malignant or indeterminate cytologic results after ultrasound-guided fine-needle aspiration. Abnormal serum thyroid hormone levels
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Amna Ahmed
    Phone
    01095339383
    Email
    amnabkar76@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Hany Seif
    Phone
    01005618665
    Email
    hanyseifrad@yahoo.com

    12. IPD Sharing Statement

    Learn more about this trial

    Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst

    We'll reach out to this number within 24 hrs